Is This the Most Bullish XRP News in an SEC Filing Ever?

The Wellgistics Health's new SEC filing has become the biggest bullish XRP news for the crypto market today. Here's why.
By Pooja Khardia
Updated: 26 Jul, 2025 | 09:36:39 AM GMT
Is This the Most Bullish XRP News in an SEC Filing Ever?

Highlights

  • Wellgistics Health has filed with the SEC to integrate XRP and XRPL, bringing a major real-world use case for Ripple.
  • Wellgistics plans to use XRP for payments, treasury reserves, collateral, and more.
  • Experts believe this SEC filing debunks the ‘XRP has no utility’ myth.

As the crypto community awaits positive news in the ongoing XRP lawsuit, another is trending in the market today. Although the Ripple vs SEC legal issue is always the centre of the topic, another debate is ‘XRP has no utility,’ where many experts allege that the token lacks utility. However, that is getting debunked soon, as a new SEC filing highlights the utility of this token.

Advertisement
Advertisement

XRP News: Wellgistics Health Plans to Integrate XRP and XRPL

According to the S-1 SEC filing, the Nasdaq-listed health company, Wellgistics Health, plans to integrate XRP and the XRPL into operations. Notably, this revolutionizes the company’s payment infrastructure, but also brings the most bullish news for the XRP holders.

Interestingly, the renowned healthcare firm intends to use XRP and XRPL to facilitate real-time, low-cost B2B transactions. More importantly, they would also raise capital through equity and debt offerings to purchase the Ripple tokens.

This way, XRP will not serve only as a reserve asset but as collateral for future financial, i.e., acting as a source to generate income. Moreover, there are also plans to spend $50M that Wellgistics gained from the LDA Capital to develop XRP infrastructure and more.

This single move alone could dispel the concerns over the Ripple token’s utility doubts.

Advertisement
Advertisement

SEC Filing Answers “XRP Has No Utility” Myth?

Under the constant pressure of the Ripple vs SEC lawsuit, the XRP price struggles, resulting in allegations over its performance and use case. Many investors and experts have doubted its performance, and even alleged that XRP would die since the RLUSD is live and whatnot. However, now, after this XRP news, experts like Marc Fagel, Ali, and others believe the end of these myths is here.

In an X post, Marc Fagel reveals that Wellgistics Health’s SEC filing is more than a simple operations plan. Instead, it is a complete blueprint for integrating it across multiple layers of corporate finance and operations, as it extensively mentions the Ripple token.

In that, XRP’s usage as treasury reserve, payment via XRPL, capital raising, collateralization, and more become the highlights.

What I have gathered from reading the S-1 form filed with the SEC today by Wellgistics Health is incredibly revealing. It is more than just a company using XRP in its treasury reserve.

This is a summary of what the filing revealed:

1. WH is not only planning to hold XRP as a…

— bill morgan (@Belisarius2020) July 25, 2025

Overall, experts believe that this is not a mere theoretical adoption but real-world utility and challenges the ‘XRP has no utility’ myth. Interestingly, crypto investor Xaif has assessed that the XRP price outperformed major altcoins with a 12.6% spike recently.

More importantly, he claimed that this is utility-driven growth, not hype, challenging the questions.

Xaif X post
Source: X, Xaif

Notably, not all are bullish on this XRP news; some, like Marc Fagel, have raised doubts on the need for a health firm to have a stockpile.

Advertisement

Frequently Asked Questions (FAQs)

1. How much is Wellgistics Health investing in XRP-related infrastructure?

The company plans to allocate $50M to develop XRP infrastructure and integration.

2. Has the XRP price responded to this news?

A significant impact is visible in the XRP price, as it surged 1.5% in the last 24 hours.

3. Does the filing disapprove of the ‘XRP has no utility’?

To some extent, experts believe that this SEC filing counters the myth.
Pooja Khardia
Pooja Khardia is a seasoned crypto content writer with 6+ years of experience in writing, including in blockchain, cryptocurrency, DeFi, and digital finance reporting. In her adventure journey, she is currently working with CoinGape Media and leading their Trending Section. Here, she uses her expertise to deliver analytics, market insights, price predictions, and information on what’s trending in the crypto space, aiming to keep the crypto and web3 community updated with market trends and important insights. Known for a user-centric and straightforward writing style, Pooja is passionate about making crypto easy and accessible. Her writing blends market research with storytelling, helping readers stay ahead in a fast-paced industry. When not behind the keyboard, Pooja embraces her creative side through drawing and crafting. Connect with Pooja on LinkedIn or X.
Why trust CoinGape: CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journalists and analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.
Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.
Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.